| Literature DB >> 32646369 |
Leonardo Correa Silva1, Rondinelle Martins Arruda1, Paula Fortuci Resende Botelho1, Leonardo Nogueira Taveira1, Kelly Menezio Giardina1, Marco Antonio de Oliveira2, Julia Dias1, Cleyton Zanardo Oliveira2, Gilberto Fava1, Denise Peixoto Guimarães3,4.
Abstract
BACKGROUND: Periampullary adenocarcinoma is a major clinical problem in high-risk patients including FAP population. A recent modification for visualizing the ampulla of Vater (AV) involves attaching a cap to the tip of the forward-viewing endoscope. Our aim was to compare the rates of complete visualization of AV using this cap-assisted endoscopy (CAE) approach to standard forward-viewing endoscopy (FVE). We also determined: (i) the rates of complications and additional sedation; (ii) the mean time required for duodenal examination; and (iii) the reproducibility among endoscopists performing this procedure.Entities:
Keywords: Ampulla of Vater; Ampullary adenoma; Ampullary carcinoma; Cap-assisted endoscopy; Forward-viewing endoscopy
Mesh:
Year: 2020 PMID: 32646369 PMCID: PMC7346639 DOI: 10.1186/s12876-020-01361-5
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Representative cases of ampulla of Vater visualization on forward-viewing endoscopy and cap-assisted endoscopy. AV completely visualized with FVE (a) and CAE (b). AV partially visualized with FVE (c) followed by CAE with completely visualization and as ampullary adenoma (d)
Fig. 2Flow diagram of patients undergoing Forward-viewing endoscopy (FVE) and Cap-assisted endoscopy (CAE) selected for the study
Demographic and baseline features of patients
| Data | |
|---|---|
| Female, n (%) | 62 (60.8) |
| Age, years | 41.7 |
| BMI, kg/m2 | 25.3 |
| Indication for EGD, n (%) | |
| FAP | 86 (84.3) |
| Ampullary neoplasia | 10 (9.8) |
| Pancreatic neoplasia | 6 (5.9) |
| Total colectomy, n (%) | 62 (72.0) |
| Spigelman stage, no (%) | |
| 0 | 21 (24.4) |
| I | 10 (11.6) |
| II | 42 (48.8) |
| III | 12 (14.0) |
| IV | 1 (1.2) |
BMI Body Mass Index, EGD esophagogastroduodenoscopy, FAP Familial Adenomatous Polyposis, SD standard deviation
Values given as mean + SD or n (%)
Comparison of ampulla of Vater visualization between FVE and CAE
| Ampulla of Vater visualization | FVE | CAE | |
|---|---|---|---|
| Completely visualized | 52 (51.0%) | 99 (97.0%) | < 0.001 |
| Partially or not visualized | 50 (49.0%) | 3a (3.0%) | < 0.001 |
FVE forward-viewing endoscopy, CAE cap-assisted endoscopy
aside-viewing endoscopy were performed
Use of sedatives during the endoscopy
| FVE | CAE | |||
|---|---|---|---|---|
| n (%) | Doses, mg | n (%) | Doses, mg | |
| Fentanyl | 102 (100.0) | 0.05 | 1 (0.9) | 0.05 |
| Midazolam | 102 (100.0) | 3.8 | 25 (24.5) | 1.9 |
| Propofol | 102 (100.0) | 51 | 79 (77.5) | 36.3 |
FVE forward-viewing endoscopy, CAE cap-assisted endoscopy
Values given as mean + SD or n(%). SD, standard deviation
The influence of the use of scopolamine on the AV visualization rate during the FVE and CAE
| Use of scopolamine | FVE | CAE | ||||
|---|---|---|---|---|---|---|
| AV visualization (%). | AV visualization (%). | |||||
| Completely visualized | Partially/not visualized | Completely Visualized | Partially/not visualized | |||
| Yes | 20 (38.5) | 14 (28.0) | 0.30 | 22 (22.2) | 2 (66.7) | 0.14 |
| No | 32 (61.5) | 36 (72.0) | 77 (77.8) | 1 (33.3) | ||
FVE forward-viewing endoscopy, CAE cap-assisted endoscopy
Values given as no
Description of endoscopic findings in both FVE and CAE
| FVE | CAE | |
|---|---|---|
| Suspicious lesion | 36 (35.2) | 46 (45.0) |
| 0 (0.0%) | 1 (1.0) | |
| Histological analysis | ||
| Negative for neoplasia | 9 (8.8) | 15 (14.7) |
| Adenocarcinoma | 1 (1.0) | 1 (1.0) |
| Adenoma | 26 (25.4) | 29 (28.4) |
FVE forward-viewing endoscopy, CAE cap-assisted endoscopy, NE not evaluated, SD standard deviation
Values given as mean + SD or n (%)